| Employment |
| No Relationships to Disclose |
|
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| Company: BlossomHill Therapeutics |
| Recipient: You |
|
| Honoraria |
| No Relationships to Disclose |
|
|
| Consulting or Advisory Role |
| Company: AstraZeneca |
| Recipient: You |
| Company: Lilly |
| Recipient: You |
| Company: EMD Serono |
| Recipient: You |
| Company: Spectrum Pharmaceuticals |
| Recipient: You |
| Company: Daiichi Sankyo/Lilly |
| Recipient: You |
| Company: Novartis |
| Recipient: You |
| Company: Hengrui Therapeutics |
| Recipient: You |
| Company: Janssen Oncology |
| Recipient: You |
| Company: Blueprint Medicines |
| Recipient: You |
| Company: sensei |
| Recipient: You |
| Company: Abbvie |
| Recipient: You |
| Company: Arrivent |
| Recipient: You |
| Company: Regeneron |
| Recipient: You |
| Company: ABION |
| Recipient: You |
| Company: Boehringer Ingelheim |
| Recipient: You |
| Company: Bayer |
| Recipient: You |
| Company: Taiho Pharmaceutical |
| Recipient: You |
| Company: Systimmune |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: Eli Lilly |
| Recipient: Your Institution |
| Company: Boehringer Ingelheim |
| Recipient: Your Institution |
| Company: arrivent |
| Recipient: Your Institution |
| Company: Teligene |
| Recipient: Your Institution |
| Company: Regeneron |
| Recipient: Your Institution |
| Company: Janssen |
| Recipient: Your Institution |
| Company: EMD Serono |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| No Relationships to Disclose |
|
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| Company: Spectrum Pharmaceuticals |
| Recipient: You |
| Company: EMD Serono |
| Recipient: You |
|
| Other Relationship |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Uncompensated Relationships |
| not answered |
|
|
| (OPTIONAL) Open Payments Link |
| not answered |
|
|